PET/CT in primary mediastinal large B-cell lymphoma responding to rituximab-CHOP: An analysis of 106 patients regarding prognostic significance and implications for subsequent radiotherapy-Reference-Cited by-同舟云学术

PET/CT in primary mediastinal large B-cell lymphoma responding to rituximab-CHOP: An analysis of 106 patients regarding prognostic significance and implications for subsequent radiotherapy

Published:2015-05-14 Issue:1 Volume:30 Page:238-242
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Vassilakopoulos T P,Pangalis G A,Chatziioannou S,Papageorgiou S,Angelopoulou M K,Galani Z,Kourti G,Prassopoulos V,Leonidopoulou T,Terpos E,Dimopoulou M N,Sachanas S,Kalpadakis C,Konstantinidou P,Boutsis D,Stefanoudaki E,Kyriazopoulou L,Siakantaris M P,Kyrtsonis M-C,Variami E,Kotsianidis I,Symeonidis A,Michali E,Katodritou E,Kokkini G,Tsatalas C,Papadaki H,Dimopoulos M-A,Sotiropoulos V,Pappa V,Karmiris T,Meletis J,Apostolidis J,Datseris I,Panayiotidis P,Konstantopoulos K,Roussou P,Rondogianni P

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/leu2015120.pdf

Reference15 articles.

1. Rieger M, Osterborg A, Pettengell R, White D, Gill D, Walewski J et al. Primary mediastinal B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: results of the Mabthera International Trial Group study. Ann Oncol 2011; 22: 664–670.

2. Vassilakopoulos TP, Pangalis GA, Katsigiannis A, Papageorgiou SG, Constantinou N, Terpos E et al. Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone with or without radiotherapy in primary mediastinal large B-cell lymphoma: The emerging standard of care. Oncologist 2012; 17: 239–249.

3. Savage KJ, Yenson PR, Shenkier T, Klasa R, Villa D, Goktepe O et al. The outcome of primary mediastinal large B-cell lymphoma (PMBCL) in the R-CHOP treatment era. Blood (ASH Annual Meeting Abstracts) 2012; 120, Abstract 303.

4. Soumerai JD, Hellmann MD, Feng Y, Sohani AR, Toomey CE, Barnes JA et al. Treatment of primary mediastinal B-cell lymphoma with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone is associated with a high rate of primary refractory disease. Leuk Lymphoma 2014; 55: 538–543.

5. Dunleavy K, Pittaluga S, Maeda LS, Advani R, Chen CC, Hessler J et al. Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma. N Engl J Med 2013; 368: 1408–1416.

Cited by 43 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cause-specific mortality in a population-level cohort of diffuse large B-cell lymphoma following chemotherapy in the early 21st century;Annals of Hematology;2024-01-16

2. Updates in the Management of Primary Mediastinal B Cell Lymphoma;Clinical Lymphoma Myeloma and Leukemia;2023-12

3. PET for Response Assessment to R-da-EPOCH in Primary Mediastinal Large B-cell lymphoma: Who Is Worthy to be Irradiated?;HemaSphere;2023-11

4. Efficacy of Residual Site Radiation Therapy (ISRT) in Patients with Primary Mediastinal Lymphoma with Deauville Score 4 Following R-CHT: Results of a Retrospective Mono Institutional Study;Journal of Clinical Medicine;2023-05-31

5. Proton Radiation Therapy After Chemotherapy in the Management of Aggressive Mediastinal Non-Hodgkin Lymphomas: A Particle Therapy Cooperative Group Lymphoma Subcommittee Collaboration;Advances in Radiation Oncology;2023-01